12 Month Price Forecast For NVCT
Distance to NVCT Price Forecasts
NVCT Price Momentum
🤔 Considering Nuvectis Pharma (NVCT)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 5, 2025 1:56 PM UTC
NVCT Analyst Ratings & Price Targets
Based on our analysis of 3 Wall Street analysts, NVCT has a consensus that is bullish. The median price target is $21.00, with forecasts ranging from $20.00 to $25.00. Currently, there are 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With NVCT currently trading at $7.00, the median price forecast suggests a 200.0% upside. The most optimistic forecast comes from at , projecting a 257.1% upside, while at provides the most conservative target, suggesting a 185.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NVCT Analyst Consensus
NVCT Price Target Range
Latest NVCT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NVCT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 6, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $21.00 |
| May 8, 2024 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $21.00 |
| Sep 15, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $21.00 |
| Mar 7, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $21.00 |
| Feb 10, 2023 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $21.00 |
| Jul 13, 2022 | Ladenburg Thalmann | Aydin Huseynov | Buy | Initiates | $21.00 |
| May 10, 2022 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $21.00 |
| Mar 2, 2022 | HC Wainwright & Co. | Buy | Initiates | $0.00 |
Stocks Similar to Nuvectis Pharma, Inc.
The following stocks are similar to Nuvectis Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Nuvectis Pharma, Inc. (NVCT) Financial Data
Nuvectis Pharma, Inc. has a market capitalization of $131.38M with a P/E ratio of -4.9x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -140.0%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Nuvectis Pharma, Inc. (NVCT) Company Overview
About Nuvectis Pharma, Inc.
Develops precision medicines for oncology treatments.
The company focuses on developing and commercializing innovative therapies for unmet medical needs in oncology, generating revenue through partnerships and potential future product sales. Its lead candidates, NXP800 and NXP900, are in clinical trials, with licensing agreements that may provide additional funding and support for development.
Nuvectis Pharma, Inc. was incorporated in 2020 and rebranded from Centry Pharma, Inc. in July 2021. The company is based in Fort Lee, New Jersey, and aims to address critical gaps in cancer treatment, particularly for patients with specific genetic mutations.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
13
CEO
Mr. Ron Bentsur M.B.A.
Country
United States
IPO Year
2021
Website
www.nuvectis.comNuvectis Pharma, Inc. (NVCT) Latest News & Analysis
Nuvectis Pharma (NVCT) has formed a hammer chart pattern, suggesting support has been found. Upward revisions in earnings estimates may indicate a potential trend reversal.
The hammer chart pattern and rising earnings estimates suggest potential price recovery for Nuvectis Pharma (NVCT), signaling a favorable buying opportunity for investors.
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
2 months agoNuvectis Pharma's NVCT stock declined following the release of Phase 1b study results for NXP800 in treating platinum-resistant ARID1a-mutated ovarian cancer.
Nuvectis Pharma's lower stock price reflects investor concerns over the Phase 1b study results for NXP800, potentially impacting future funding and development of its cancer treatments.
Nuvectis Pharma (NVCT) is highlighted as a potential investment for shorter-term traders, having passed a screening for fundamentally sound stocks.
Nuvectis Pharma's positive price trend and strong fundamentals suggest potential short-term gains, attracting investors seeking quick returns in the stock market.
Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know
2 months agoNuvectis Pharma (NVCT) has a consensus price target suggesting a 169.9% upside potential, with recent earnings estimate revisions indicating potential near-term stock gains.
A 169.9% price target suggests significant growth potential for Nuvectis Pharma, and rising earnings estimates may indicate a bullish sentiment, attracting investor interest.
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
3 months agoNuvectis Pharma (NASDAQ: NVCT) reported Q3 2024 financial results and business updates. The company focuses on precision medicines for oncology and unmet medical needs.
Nuvectis Pharma's Q3 financial results and business updates signal its current performance and future potential, influencing stock valuation and investor confidence in the biotech sector.
Nuvectis Pharma (NASDAQ: NVCT) shows promise with its SRC/YES1 inhibitor NXP900, which displayed strong synergy with ALK inhibitors in NSCLC. NXP800 is in Phase 1b trials.
Nuvectis Pharma's drug developments, particularly NXP900's synergy with ALK inhibitors in resistant NSCLC, signal potential breakthroughs that could enhance market competitiveness and drive stock value.
Frequently Asked Questions About NVCT Stock
What is Nuvectis Pharma, Inc.'s (NVCT) stock forecast for 2025?
Based on our analysis of 3 Wall Street analysts, Nuvectis Pharma, Inc. (NVCT) has a median price target of $21.00. The highest price target is $25.00 and the lowest is $20.00.
Is NVCT stock a good investment in 2025?
According to current analyst ratings, NVCT has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $7.00. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for NVCT stock?
Wall Street analysts predict NVCT stock could reach $21.00 in the next 12 months. This represents a 200.0% increase from the current price of $7.00. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nuvectis Pharma, Inc.'s business model?
The company focuses on developing and commercializing innovative therapies for unmet medical needs in oncology, generating revenue through partnerships and potential future product sales. Its lead candidates, NXP800 and NXP900, are in clinical trials, with licensing agreements that may provide additional funding and support for development.
What is the highest forecasted price for NVCT Nuvectis Pharma, Inc.?
The highest price target for NVCT is $25.00 from at , which represents a 257.1% increase from the current price of $7.00.
What is the lowest forecasted price for NVCT Nuvectis Pharma, Inc.?
The lowest price target for NVCT is $20.00 from at , which represents a 185.7% increase from the current price of $7.00.
What is the overall NVCT consensus from analysts for Nuvectis Pharma, Inc.?
The overall analyst consensus for NVCT is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $21.00.
How accurate are NVCT stock price projections?
Stock price projections, including those for Nuvectis Pharma, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
